Publications & References

Platform Publications

• Boyden, E., Zhang, F., Bamberg, E., et al. (2005). Millisecond-timescale, genetically targeted optical control of neural activity. Nature Neuroscience, 8(10), 1263–1268. https://pubmed.ncbi.nlm.nih.gov/16116447/
• Zhang, F., Wang, L. P., Brauner, M., et al. (2007). Multimodal fast optical interrogation of neural circuitry. Nature, 446(7136), 633–639. https://pubmed.ncbi.nlm.nih.gov/17410168/
• Kravitz, A. V., Freeze, B. S., Parker, P. R. L., Kay, K., Thwin, M. T., Deisseroth, K., & Kreitzer, A. C. (2010). Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature, 466(7306), 622–626. https://pubmed.ncbi.nlm.nih.gov/20613723/
• Wang, X., Allen, W. E., Wright, M. A., Sylwestrak, E. L., Samusik, N., Vesuna, S., Evans, K., Liu, C., Ramakrishnan, C., Liu, J., Nolan, G. P., Bava, F.-A., & Deisseroth, K. (2018). Three-dimensional intact-tissue sequencing of single-cell transcriptional states. Science, 361(6400), eaat5691. https://pubmed.ncbi.nlm.nih.gov/29930089/

References

• Ropacki, S. A., & Jeste, D. V. (2005). Epidemiology of and risk factors for psychosis of Alzheimer’s disease: A review of 55 studies published from 1990 to 2003. American Journal of Psychiatry, 162(11), 2022–2030. https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.162.11.2022
• Bakker, G., Vingerhoets, C., Boucherie, D., Caan, M., Bloemen, O., Eersels, J., Booij, J., & van Amelsvoort, T. (2018). Relationship between muscarinic M1 receptor binding and cognition in medication-free subjects with psychosis. NeuroImage: Clinical, 18, 713–719. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857491/
• Kane, J. M., Agid, O., Baldwin, M. L., Howes, O., Lindenmayer, J.-P., Marder, S., Olfson, M., Potkin, S. G., & Correll, C. U. (2019). Clinical guidance on the identification and management of treatment-resistant schizophrenia. Journal of Clinical Psychiatry, 80(2), 18ac12023. https://www.psychiatrist.com/jcp/clinical-guidance-on-treatment-resistant-schizophrenia/
• Dean, B., Bakker, G., Ueda, H. R., Tobin, A. B., Brown, A., & Kanaan, R. A. A. (2023). A growing understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia. Frontiers in Cellular Neuroscience, 17, 1124333. https://doi.org/10.3389/fncel.2023.1124333
• Meyer, J. M., & Correll, C. U. (2023). Increased metabolic potential, efficacy, and safety of emerging treatments in schizophrenia. CNS Drugs, 37(7), 545–570. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374807/
• Yohn, C. N., Weiden, P. J., Felder, C. C., & Stahl, S. M. (2022). Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2021.11.002